1
|
Tzeis S, Tsiachris D, Kourouklis SP, Patsourakos F, Karlis D, Kouskos G, Gavriilidou M, Koufaki P, Vatkalis N, Kapetanios K, Papadimitriou G, Taxiarchou E, Giannakoulas G. 6082A prospective, multicenter, nationwide, observational study of flecainide controlled release on the quality of life of patients with atrial fibrillation in Greece, the REFLEC-CR study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a considerable impact on patients' quality of life (QoL). Flecainide acetate, is a class Ic antiarrhythmic agent, recommended as first line treatment in AF patients without underlying structural heart disease.
Purpose
This prospective, multicenter, nationwide, observational study aimed to evaluate the effect of oral treatment with controlled-release (CR) flecainide administered once daily on AF patients' QoL and treatment compliance during a 12-week period.
Methods
A total of 70 cardiologists participated in the study enrolling consecutive adult patients with paroxysmal or persistent AF, treated with flecainide CR in the context of a rhythm control strategy. The effect on QoL was assessed by the Canadian Cardiovascular Society Severity of Atrial Fibrillation scale (CCS-SAF) measured at baseline and at 12 weeks of treatment.
Results
In total, 679 patients (53.2% females, mean age 65.9±11.7 years, 86.9% paroxysmal AF) were included in the analysis. At least one prior antiarrhythmic treatment was documented in 43.8% of patients. The initial daily dose of flecainide CR was 100mg in 71.7% of the patients, with a titration to 200mg by the end of study achieved in 67%. In 93.6% of patients an excellent compliance score (100%) to treatment was recorded at the end of the study period. Treatment with flecainide CR resulted in a significant improvement in QoL as presented in the table.
Table 1 CCS-SAF score Baseline (Week 0) End of study visit (Week 12) N=679 N=634 Class 1 (minimal effect on QoL) 343 (50.5) 464 (73.2) Class 2 (minor effect on QoL) 253 (37.2) 140 (22.1) Class 3 (moderate effect on QoL) 73 (10.8) 28 (4.4) Class 4 (severely impairs QoL) 10 (1.5) 2 (0.3) CCS-SAF continuous score Mean ± SD 1.64±0.73 1.32±0.57 Change from baseline‡ Mean (95% CI) −0.325 (−0.379, −0.271) p-value <0.0001 ‡Paired t-test is used.
Conclusions
This prospective, multicenter, observational study demonstrated that treatment of AF patients with flecainide CR, was associated with a significant improvement of QoL and excellent compliance to treatment.
Acknowledgement/Funding
Sponsored by WinMedica S.A.
Collapse
Affiliation(s)
- S Tzeis
- Mitera General Hospital, Cardiology Department, Athens, Greece
| | - D Tsiachris
- Athens Medical Center, Electrophysiology and Pacing Department, Athens, Greece
| | - S P Kourouklis
- Hygeia Hospital, Electrophysiology, Pacemaker and ICD Unit, Athens, Greece
| | | | - D Karlis
- Private practice, Tripoli, Greece
| | | | - M Gavriilidou
- Hospital Papageorgiou, Cardiology Department, Thessaloniki, Greece
| | - P Koufaki
- WinMedica S.A., Medical Department, Athens, Greece
| | | | | | | | | | - G Giannakoulas
- Ahepa University Hospital, Cardiology Department, Thessaloniki, Greece
| |
Collapse
|
2
|
Pyrros J, Rallides L, Simeonides D, Kouskos G, Kapogianni M, Stamatis D, Flessas L. Dyslipidaemias and smoking are the most important risk factors for premature coronary disease in Greek non-diabetic men. Atherosclerosis 1995. [DOI: 10.1016/0021-9150(95)96303-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|